GSEA of DNMT3A-mutant T-ALL samples comparing the dimethyl sulfoxide (DMSO) control with DEX + RUX treatment identified 4 differential gene sets: “E2F targets I,” “MTORC1 signaling,” “G2M checkpoint,” and “IL2 / STAT5 signaling”; all downregulated after DEX + RUX treatment (Figure 6A). The gene discussed is DNMT3A; the disease is acute lymphoblastic leukemia.